Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 57 articles:
HTML format

Single Articles

    January 2022
  1. SANGSTER AG, Gooding RJ, Garven A, Ghaedi H, et al
    Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer.
    PLoS One. 2022;17:e0259992.
    PubMed     Abstract available

  2. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.
    PLoS One. 2022;17:e0261124.
    PubMed     Abstract available

  3. FU Y, Sun S, Bi J, Kong C, et al
    An HDAC9-associated immune-related signature predicts bladder cancer prognosis.
    PLoS One. 2022;17:e0264527.
    PubMed     Abstract available

  4. ISONO M, Okubo K, Asano T, Sato A, et al
    Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
    PLoS One. 2022;17:e0266476.
    PubMed     Abstract available

  5. KANG DH, Cho KS, Moon YJ, Chung DY, et al
    Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation.
    PLoS One. 2022;17:e0267410.
    PubMed     Abstract available

  6. AGHAMIR SMK, Khatami F, Farrokhpour H, Oliveira Reis L, et al
    Oncologic outcomes of Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis.
    PLoS One. 2022;17:e0267934.
    PubMed     Abstract available

  7. OKORIE CL, Gatsby E, Schroeck FR, Ould Ismail AA, et al
    Using electronic health records to streamline provider recruitment for implementation science studies.
    PLoS One. 2022;17:e0267915.
    PubMed     Abstract available

  8. Retraction: MicroRNA-137 Upregulation Increases Bladder Cancer Cell Proliferation and Invasion by Targeting PAQR3.
    PLoS One. 2022;17:e0269903.

  9. ABDELGAWAD A, Hashem A, Mosbah A, Eissa LA, et al
    A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer.
    PLoS One. 2022;17:e0266371.
    PubMed     Abstract available

  10. GULYAS D, Kovacs G, Jankovics I, Meszaros L, et al
    Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody and toll-like receptor agonists: Unmethylated CpG and LPS on an MB49 bladder cancer cell line in a mouse model.
    PLoS One. 2022;17:e0270802.
    PubMed     Abstract available

  11. GLEICHENHAGEN J, Arndt C, Casjens S, Topfer C, et al
    Exploring solid-phase proximity ligation assay for survivin detection in urine.
    PLoS One. 2022;17:e0270535.
    PubMed     Abstract available

  12. JURI H, Higashiyama A, Yamamoto K, Narumi Y, et al
    Comparison of reduced field-of-view DWI and full field-of view DWI for the differentiation between non-muscle invasive bladder cancer and muscle invasive bladder cancer using VI-RADS.
    PLoS One. 2022;17:e0271470.
    PubMed     Abstract available

  13. DE WISPELAERE N, Rico SD, Bauer M, Luebke AM, et al
    High prevalence of p16 staining in malignant tumors.
    PLoS One. 2022;17:e0262877.
    PubMed     Abstract available

  14. LUND HAHEIM L, Thelle DS, Ronningen KS, Olsen I, et al
    Low level of antibodies to the oral bacterium Tannerella forsythia predicts bladder cancers and Treponema denticola predicts colon and bladder cancers: A prospective cohort study.
    PLoS One. 2022;17:e0272148.
    PubMed     Abstract available

  15. GILLEZEAU C, Movva N, van Gerwen M, Rabon-Stith K, et al
    Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients.
    PLoS One. 2022;17:e0271339.
    PubMed     Abstract available

  16. MOON YJ, Cho KS, Jeong JY, Chung DY, et al
    Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): Systematic review and network meta-analysis according to EAU COVID-19 recommendations.
    PLoS One. 2022;17:e0273733.
    PubMed     Abstract available

  17. HOLMBERG L, Hagberg O, Haggstrom C, Gardmark T, et al
    Number of transurethral procedures after non-muscle-invasive bladder cancer and survival in causes other than bladder cancer.
    PLoS One. 2022;17:e0274859.
    PubMed     Abstract available

    January 2021
  18. LAYTRAGOON LEWIN N, Karlsson JE, Robinsson D, Fagerberg M, et al
    Influence of single nucleotide polymorphisms among cigarette smoking and non-smoking patients with coronary artery disease, urinary bladder cancer and lung cancer.
    PLoS One. 2021;16:e0243084.
    PubMed     Abstract available

  19. BESSA A, Rammant E, Enting D, Bryan RT, et al
    The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature.
    PLoS One. 2021;16:e0243136.
    PubMed     Abstract available

  20. LIEDBERG F, Hagberg O, Aljabery F, Gardmark T, et al
    Cumulative incidence of midline incisional hernia and its surgical treatment after radical cystectomy and urinary diversion for bladder cancer: A nation-wide population-based study.
    PLoS One. 2021;16:e0246703.
    PubMed     Abstract available

  21. HUANG CY, Wang SC, Chan L, Hsieh TY, et al
    Gender differences in trends of bladder cancer mortality-to-incidence ratios according to health expenditure in 55 countries.
    PLoS One. 2021;16:e0244510.
    PubMed     Abstract available

  22. UYSAL D, Kowalewski KF, Kriegmair MC, Wirtz R, et al
    A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer.
    PLoS One. 2021;16:e0248342.
    PubMed     Abstract available

  23. WANG K, Yang JC, Jang YJ, Chen GY, et al
    19-(Benzyloxy)-19-oxojolkinolide B (19-BJB), an ent-abietane diterpene diepoxide, inhibits the growth of bladder cancer T24 cells through DNA damage.
    PLoS One. 2021;16:e0248468.
    PubMed     Abstract available

  24. JIANG H, Gu X, Zuo Z, Tian G, et al
    Prognostic value of circulating tumor cells in patients with bladder cancer: A meta-analysis.
    PLoS One. 2021;16:e0254433.
    PubMed     Abstract available

  25. MUILWIJK T, Akand M, Daelemans S, Marien K, et al
    Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.
    PLoS One. 2021;16:e0257195.
    PubMed     Abstract available

  26. KLOSE K, Packeiser EM, Muller P, Granados-Soler JL, et al
    Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
    PLoS One. 2021;16:e0257403.
    PubMed     Abstract available

  27. LEE YH, Lee MM, De Silva DM, Roy A, et al
    Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder.
    PLoS One. 2021;16:e0241766.
    PubMed     Abstract available

  28. ZLOWOCKA-PERLOWSKA E, Debniak T, Slojewski M, van de Wetering T, et al
    Survival of bladder or renal cancer in patients with CHEK2 mutations.
    PLoS One. 2021;16:e0257132.
    PubMed     Abstract available

  29. CHANG YH, Tam HL, Lu MC, Huang HS, et al
    Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells.
    PLoS One. 2021;16:e0254011.
    PubMed     Abstract available

  30. KIM SH, Song MK, Ku JH, Kang SH, et al
    A retrospective multicenter comparison of conditional cancer-specific survival between laparoscopic and open radical nephroureterectomy in locally advanced upper tract urothelial carcinoma.
    PLoS One. 2021;16:e0255965.
    PubMed     Abstract available

  31. INKOL JM, Hocker SE, Mutsaers AJ
    Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells.
    PLoS One. 2021;16:e0255591.
    PubMed     Abstract available

  32. HE X, Anthony DC, Catoni Z, Cao W, et al
    Pulmonary tumor embolism: A retrospective study over a 30-year period.
    PLoS One. 2021;16:e0255917.
    PubMed     Abstract available

  33. ODA S, Fujisawa M, Chunning L, Ito T, et al
    Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder.
    PLoS One. 2021;16:e0254289.
    PubMed     Abstract available

  34. AL-EZZI EM, Veitch ZW, Salah SH, Van der Kwast TH, et al
    Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study.
    PLoS One. 2021;16:e0259272.
    PubMed     Abstract available

  35. LEMINSKI A, Kaczmarek K, Byrski T, Slojewski M, et al
    Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
    PLoS One. 2021;16:e0259526.
    PubMed     Abstract available

    January 2020
  36. CHEN Q, Fu L
    Upregulation of long non-coding RNA ROR1-AS1 promotes cell growth and migration in bladder cancer by regulation of miR-504.
    PLoS One. 2020;15:e0227568.
    PubMed     Abstract available

  37. EVERS J, Grotenhuis AJ, Aben KKH, Kiemeney LALM, et al
    No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression.
    PLoS One. 2020;15:e0229384.
    PubMed     Abstract available

  38. REZAEE ME, Lynch KE, Li Z, MacKenzie TA, et al
    The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
    PLoS One. 2020;15:e0230417.
    PubMed     Abstract available

  39. LILLESAND M, Kvikstad V, Mangrud OM, Gudlaugsson E, et al
    Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer.
    PLoS One. 2020;15:e0233676.
    PubMed     Abstract available

  40. PACKEISER EM, Hewicker-Trautwein M, Thiemeyer H, Mohr A, et al
    Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
    PLoS One. 2020;15:e0230272.
    PubMed     Abstract available

  41. HANKE M, Dubois J, Kausch I, Petkovic S, et al
    Oncoprotein 18 is necessary for malignant cell proliferation in bladder cancer cells and serves as a G3-specific non-invasive diagnostic marker candidate in urinary RNA.
    PLoS One. 2020;15:e0229193.
    PubMed     Abstract available

  42. MEHUS AA, Bergum N, Knutson P, Shrestha S, et al
    Activation of PPARgamma and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells.
    PLoS One. 2020;15:e0237976.
    PubMed     Abstract available

  43. HUTTANUS HM, Vu T, Guruli G, Tracey A, et al
    Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.
    PLoS One. 2020;15:e0237070.
    PubMed     Abstract available

  44. SANTOS-SANCHEZ V, Cordoba-Dona JA, Viciana F, Escolar-Pujolar A, et al
    Geographical variations in cancer mortality and social inequalities in southern Spain (Andalusia). 2002-2013.
    PLoS One. 2020;15:e0233397.
    PubMed     Abstract available

  45. REED O, Jubber I, Griffin J, Noon AP, et al
    Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes.
    PLoS One. 2020;15:e0239338.
    PubMed     Abstract available

  46. TELEKA S, Hindy G, Drake I, Poveda A, et al
    Blood pressure and bladder cancer risk in men by use of survival analysis and in interaction with NAT2 genotype, and by Mendelian randomization analysis.
    PLoS One. 2020;15:e0241711.
    PubMed     Abstract available

  47. AZUMA T, Sato Y, Ohno T, Azuma M, et al
    Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer.
    PLoS One. 2020;15:e0243379.
    PubMed     Abstract available

  48. Retraction: MicroRNA-214 Suppresses Oncogenesis and Exerts Impact on Prognosis by Targeting PDRG1 in Bladder Cancer.
    PLoS One. 2020;15:e0244274.

  49. KARDOS J, Rose TL, Manocha U, Wobker SE, et al
    Development and validation of a NanoString BASE47 bladder cancer gene classifier.
    PLoS One. 2020;15:e0243935.
    PubMed     Abstract available

    January 2019
  50. FANG CW, Hsieh VC, Huang SK, Tsai IJ, et al
    A population-based cohort study examining the association of documented bladder diverticulum and bladder cancer risk in urology patients.
    PLoS One. 2019;14:e0222875.
    PubMed     Abstract available

  51. KIM MJ, Chi BH, Yoo JJ, Ju YM, et al
    Structure establishment of three-dimensional (3D) cell culture printing model for bladder cancer.
    PLoS One. 2019;14:e0223689.
    PubMed     Abstract available

  52. GRIFFITHS GO, Cowan RA, Grigor KM, Uscinska BM, et al
    BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract.
    PLoS One. 2019;14:e0210785.
    PubMed     Abstract available

  53. GOFRIT ON, Klein BY, Cohen IR, Ben-Hur T, et al
    Bacillus Calmette-Guerin (BCG) therapy lowers the incidence of Alzheimer's disease in bladder cancer patients.
    PLoS One. 2019;14:e0224433.
    PubMed     Abstract available

  54. HE S, Carman CV, Lee JH, Lan B, et al
    The tumor suppressor p53 can promote collective cellular migration.
    PLoS One. 2019;14:e0202065.
    PubMed     Abstract available

  55. RYTLEWSKI J, Deng S, Xie T, Davis C, et al
    Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood.
    PLoS One. 2019;14:e0213684.
    PubMed     Abstract available

  56. ETO S, Saeki K, Yoshitake R, Yoshimoto S, et al
    Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.
    PLoS One. 2019;14:e0218382.
    PubMed     Abstract available

  57. ABECASSIS J, Hamy AS, Laurent C, Sadacca B, et al
    Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data.
    PLoS One. 2019;14:e0224143.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.